

# 1 Limit of Detection for Rapid Antigen Testing of the SARS-CoV-2 Omicron Variant

2

3 Sydney Stanley<sup>1</sup>, Donald J. Hamel<sup>1</sup>, Ian D. Wolf<sup>1</sup>, Stefan Riedel<sup>2,3</sup>, Sanjuncta Dutta<sup>2</sup>, Annie

4 Cheng<sup>2</sup>, James E. Kirby<sup>\*#2,3</sup>, Phyllis J. Kanki<sup>\*#1</sup>

5

6 <sup>1</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public

7 Health, Boston, Massachusetts, USA

8 <sup>2</sup>Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

9 <sup>3</sup>Harvard Medical School, Boston, Massachusetts, USA

10

11 \*Co-Senior Authors

12

13 Address for correspondence:

14 Phyllis J. Kanki, DVM, PhD

15 651 Huntington Avenue

16 FXB Building, Room 405B

17 Boston, Massachusetts 02115

18 617.432.1267

19 [pkanki@hsph.harvard.edu](mailto:pkanki@hsph.harvard.edu)

20

21 James E. Kirby, MD

22 Beth Israel Deaconess Medical Center

23 330 Brookline Avenue – YA309

24 Boston MA 02215

25 617-667-3648

26 [jekirby@bidmc.harvard.edu](mailto:jekirby@bidmc.harvard.edu)

27

28

29

30 **Keywords:** COVID-19, SARS-CoV-2, antigen test, Omicron, limit of detection, analytical

31 sensitivity

32

33 **Abstract**

34 There has been debate in the literature about the ability of antigen tests to detect the SARS-CoV-  
35 2 Omicron variant including indication on the US Food and Drug administration website that  
36 antigen tests may have lower sensitivity for the Omicron variant without provision of data or the  
37 potential scale of the issue (see [https://www.fda.gov/medical-devices/coronavirus-covid-19-and-](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests)  
38 [medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests](https://www.fda.gov/medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests) - [omicronvariantimpact](#),  
39 accessed 1/27/2022). Here we determined the limit of detection (LoD) for the Omicron variant  
40 compared with the WA1 strain used for LoD studies described in the Instructions for Use for all  
41 Emergency Use Authorization (EUA)-approved antigen tests. Using live virus (to avoid artifactual  
42 findings potentially obtained with gamma-irradiated or heat-killed virus) quantified by plaque  
43 forming units (PFU), we examined the analytical sensitivity of three antigen tests widely used in  
44 the United States: the Abbott Binax Now, the AccessBio CareStart , and LumiraDx antigen tests.  
45 We found that the 95% detection threshold (LoD) for antigen tests was at least as good for Omicron  
46 as for the WA1 strain. Furthermore, the relationship of genome copies to plaque forming units for  
47 Omicron and WA1 overlap. Therefore, the LoD equivalency also applies if the quantitative  
48 comparator is genome copies determined from live virus preparations. Taken together, our data  
49 support the continued ability of the antigen tests examined to detect the Omicron variant.

50

51

52

53


54 To bolster COVID-19 pandemic mitigation efforts, the U.S. Food and Drug Administration  
55 (FDA) issued Emergency Use Authorization (EUA) for easy-to-use rapid antigen tests  
56 instrumental for diagnosis and surveillance of SARS-CoV-2 infection (1-2). Unlike sensitive  
57 molecular tests that detect multiple SARS-CoV-2 genes, antigen tests target a singular yet  
58 genetically-conserved nucleocapsid viral protein (3-6). As the pandemic continues, some  
59 hypothesized that new SARS-CoV-2 variants might compromise antigen test performance. This  
60 concern heightened with the spread of Omicron, the B.1.1.529 variant of concern (VoC) that  
61 caused 99.5% of SARS-CoV-2 infections in the United States early 2022 (7-8). Beyond the  
62 striking 36 amino acid mutations in the spike protein, Omicron also harbors P13L,  $\Delta$ 31- 33,  
63 R203K, and G204R nucleocapsid mutations (9). The limit of detection (LoD) of many FDA EUA  
64 antigen tests were established with gamma-irradiated or heat-inactivated preparations of the USA  
65 WA1/2020 (WA1) reference strain (13) lacking nucleocapsid mutations. This includes at-home  
66 lateral flow tests like the BinaxNOW COVID-19 Ag Card (Abbott Diagnostics Scarborough, Inc.,  
67 Scarborough, ME) and the CareStart COVID-19 Antigen Home Test (Access Bio, Inc., Somerset,  
68 NJ), and the LumiraDx SARS-CoV-2 Ag Test (LumiraDx UK Ltd., Alloa, Great Britain), a  
69 microfluidic immunofluorescence assay for clinical laboratory testing (10-12). In the present  
70 study, we used cultured plaque-titered live Omicron and WA1 virus to assess differences in the  
71 LoD with the Binax, CareStart, and LumiraDx tests.

72 The WA1 (13) and Omicron lh01 (NCBI accession OL719310) virus were titered with  
73 standard plaque (13) and calibrated RT-qPCR (14) assays. Ten-fold serial dilutions in PBS ranging  
74 from  $2.5 \times 10^4$  to 2.5 plaque forming units (PFU)/mL were applied to swabs in 50uL volumes and  
75 tested in triplicate according to manufacturer instructions (10-12). Binax and CareStart kits  
76 contained all required consumables; iClean foam swabs (Supera CY-FS742, Houston, TX) were

77 used with the LumiraDx test. After identifying the lowest 10-fold dilution with three replicate  
78 positive tests, we iteratively tested 3-fold dilutions around this concentration until identifying the  
79 lowest dilution (the LoD) in which at least 19 of 20 replicates ( $\geq 95\%$ ) were positive.

80 The LumiraDx LoD for both Omicron and WA1 was  $2.5 \times 10^2$  PFU/mL (12.5 PFU/swab or  
81  $1.0 \times 10^6$  genome copies (gc)/swab) (Fig. 1). The Binax LoD was  $8.3 \times 10^1$  PFU/mL (4.2 PFU/swab,  
82  $3.4 \times 10^5$  gc/swab) and  $2.5 \times 10^2$  PFU/mL (12.5 PFU/swab,  $1.0 \times 10^6$  gc/swab) for Omicron and WA1,  
83 respectively. The CareStart LoD was  $2.8 \times 10^3$  PFU/mL ( $1.4 \times 10^2$  PFU/swab,  $1.1 \times 10^7$  gc/swab) and  
84  $8.3 \times 10^3$  PFU/mL ( $4.2 \times 10^2$  PFU/swab,  $3.5 \times 10^7$  gc/swab) for Omicron and WA1, respectively. The  
85 nearly identical relationship of PFU to genome copies for each variant indicates that the Omicron  
86 variant mutations do not change underlying diagnostic relationships and parameters (Figure 2).  
87 Our use of live virus, analyte volume, and swab type may explain the slight discrepancy with the  
88 manufacturers' LoDs. Our findings are consistent with similar investigations, but these studies fell  
89 short of the FDA's EUA requirement of 20 LoD replicates or included tests unavailable in the  
90 United States (15-17). In all, we demonstrate that the rapid antigen tests evaluated detect Omicron  
91 effectively, allaying concerns on the impact of the nucleocapsid mutations. Rapid antigen tests  
92 remain critical public health tools towards reducing SARS-CoV-2 variant transmission.


93 **Figure 1. Limit of detection of the antigen tests.** Limit of detection (LoD) in PFU/mL determined  
94 in our analysis (bars). Dotted lines reference the manufacturer reported LoD in respective  
95 Instructions for Use (IFU) documents (10-12), converted from TCID<sub>50</sub>/mL to PFU/mL by  
96 multiplying the TCID<sub>50</sub>/mL by 0.7, a standard conversion based on the Poisson distribution:  
97 LumiraDx (32 TCID<sub>50</sub>/mL, 2.2x10<sup>1</sup> PFU/mL); Binax (140 TCID<sub>50</sub>/mL, 9.8x10<sup>1</sup> PFU/mL),  
98 CareStart (800 TCID<sub>50</sub>/mL, 5.6x10<sup>2</sup> PFU/mL).  
99



101 **Figure 2. Correlation of PFU/mL and viral load in genome copies/mL.** Stocks of each strain  
102 was serially diluted 10-fold in PBS and analyzed by PFU (13) and calibrated RT-qPCR assays  
103 (14). Both axes are on a Log10 scale.

104

105



106 **References**

107

108 1. The U.S. Food and Drug Administration. In Vitro Diagnostics EUAs - Antigen Diagnostic

109 Tests for SARS-CoV-2. Available at: [https://www.fda.gov/medical-devices/coronavirus-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro)

110 [disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro)

111 [diagnostics-euas-antigen-diagnostic-tests-sars-cov-2](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2). Accessed 24 January 2022.

112 2. The Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2,

113 the virus that causes COVID-19. Available at: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html)

114 [ncov/hcp/testing-overview.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html). Accessed 24 January 2022.

115 3. Jegerlehner S, Suter-Riniker F, Jent P, Bittel P, Nagler M. 2021. Diagnostic accuracy of a

116 SARS-CoV-2 rapid antigen test in real-life clinical settings. *Int J Infect Dis* 109:118-122.

117 4. Allan-Blitz LT, Klausner JD. 2021. A Real-World Comparison of SARS-CoV-2 Rapid

118 Antigen Testing versus PCR Testing in Florida. *J Clin Microbiol* 59(10):e0110721.

119 5. Pray IW, Ford L, Cole D, Lee C, Bigouette JP, Abedi GR, Bushman D, Delahoy MJ, Currie

120 D, Cherney B, Kirby M, Fajardo G, Caudill M, Langolf K, Kahrs J, Kelly P, Pitts C, Lim

121 A, Aulik N, Tamin A, Harcourt JL, Queen K, Zhang J, Whitaker B, Browne H, Medrzycki

122 M, Shewmaker P, Folster J, Bankamp B, Bowen MD, Thornburg NJ, Goffard K, Limbago

123 B, Bateman A, Tate JE, Gieryn D, Kirking HL, Westergaard R, Killerby M, CDC COVID-

124 19 Surge Laboratory Group. 2021. Performance of an Antigen-Based Test for

125 Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses -

126 Wisconsin, September-October 2020. *MMWR Morb Mortal Wkly Rep*. 2021 Jan 1

127 69(5152):1642-1647.

- 128 6. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. 2020. A Sequence  
129 Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune  
130 Responses to SARS-CoV-2. *Cell Host Microbe* 27(4):671-680.e2.
- 131 7. The World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2  
132 Variant of Concern. Available at: [https://www.who.int/news/item/26-11-2021-](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)  
133 [classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern). Accessed 21 January  
134 2022.
- 135 8. The Centers for Disease Control and Prevention. Monitoring Variant Proportions.  
136 Available at: <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>. Accessed 21  
137 January 2022.
- 138 9. Nextstrain. Genomic epidemiology of novel coronavirus - Global subsampling. Available  
139 at: <https://nextstrain.org/ncov/gisaid/global>. Accessed 21 January 2022.
- 140 10. SARS-CoV-2 Antigen (Ag) Product Insert – LumiraDx. Available at:  
141 [https://www.lumiradx.com/assets/pdfs/covid-19-antigen-test/sars-cov-2-antigen-product-](https://www.lumiradx.com/assets/pdfs/covid-19-antigen-test/sars-cov-2-antigen-product-insert/sars-cov-2-ag-test-strip-product-insert-eua.pdf?v=6)  
142 [insert/sars-cov-2-ag-test-strip-product-insert-eua.pdf?v=6](https://www.lumiradx.com/assets/pdfs/covid-19-antigen-test/sars-cov-2-antigen-product-insert/sars-cov-2-ag-test-strip-product-insert-eua.pdf?v=6). Accessed 21 January 2022.
- 143 11. BinaxNOW COVID-19 Ag Card – Instructions for Use. Available at:  
144 <https://www.fda.gov/media/141570/download>. Accessed 21 January 2022.
- 145 12. CareStart COVID-19 Antigen test – Instructions for Use. Available at  
146 <https://www.fda.gov/media/142919/download>. Accessed 21 January 2022.
- 147 13. Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, Queen K, Tao Y, Paden  
148 CR, Zhang J, Li Y, Uehara A, Wang H, Goldsmith C, Bullock HA, Wang L, Whitaker B,  
149 Lynch B, Gautam R, Schindewolf C, Lokugamage KG, Scharon D, Plante JA,  
150 Mirchandani D, Widen SG, Narayanan K, Makino S, Ksiazek TG, Plante KS, Weaver SC,



- 151 Lindstrom S, Tong S, Menachery VD, Thornburg NJ. 2020. Severe Acute Respiratory  
152 Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. *Emerg*  
153 *Infect Dis* 26(6):1266-1273.
- 154 14. Kirby JE, Riedel S, Dutta S, Arnaout R, Cheng A, Ditelberg S, Donald J. Hamel, Charlotte  
155 A. Chang, Phyllis J. Kanki. 2021. SARS-CoV-2 Antigen Tests Predict Infectivity Based  
156 on Viral Culture: Comparison of Antigen, PCR Viral Load, and Viral Culture Testing on a  
157 Large Sample Cohort. medRxiv 2021 <https://doi.org/10.1101/2021.12.22.21268274>.
- 158 15. Regan J, Flynn JP, Choudhary MC, Uddin R, Lemieux J, Boucau J, Bhattacharyya RP,  
159 Barczak AK, Li JZ, Siedner MJ. 2021. Detection of the omicron variant virus with the  
160 Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay. medRxiv  
161 <https://doi.org/10.1101/2021.12.22.21268219>.
- 162 16. Bekliz M, Perez-Rodriguez F, Puhach O, Adea K, Melancia SM, Baggio S, Corvaglia AR,  
163 Jacquerioz-Bausch F, Alvarez C, Essaidi-Laziosi M, Escadafal C, Kaiser L, Eckerle I.  
164 2022. Sensitivity of SARS-CoV-2 antigen-detecting rapid tests for Omicron variant.  
165 medRxiv <https://doi.org/10.1101/2021.12.18.21268018>.
- 166 17. Deerain J, Druce J, Tran T, Batty M, Yoga Y, Fennell M, Dwyer DE, Kok J, Williamson  
167 DA. 2021. Assessment of the analytical sensitivity of ten lateral flow devices against the  
168 SARS-CoV-2 omicron variant. *J Clin Microbiol* jcm-02479.